(R)-SR-C-107 is an orally active inhibitor developed based on ENL (containing YEAST domain protein), designed to target acute myeloid leukemia (AML). The inhibitor has an IC50 of 40 nM and a KD of 144 nM for ENL. In a xenograft mouse model of AML, (R)-SR-C-107 demonstrated in vivo efficacy, achieving a tumor regression rate of 45% at a dosage of 200 mg/kg (PO, QD).
Molekulargewicht:
389.45
Formel:
C21H23N7O
Target-Kategorie:
Epigenetic Reader Domain
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
